|1.||Nimmagadda, Sridhar: 2 articles (08/2014 - 06/2011)|
|2.||Pomper, Martin G: 2 articles (08/2014 - 06/2011)|
|3.||De Silva, Ravindra A: 2 articles (08/2014 - 06/2011)|
|4.||Pullambhatla, Mrudula: 2 articles (08/2014 - 06/2011)|
|5.||Konopleva, Marina: 2 articles (01/2013 - 06/2009)|
|6.||Ling, Xiaoyang: 2 articles (01/2013 - 06/2009)|
|7.||Andreeff, Michael: 2 articles (01/2013 - 06/2009)|
|8.||Fricker, Simon P: 2 articles (10/2009 - 08/2006)|
|9.||Bridger, Gary J: 2 articles (10/2009 - 08/2006)|
|10.||van Waarde, A: 1 article (11/2014)|
01/01/2013 - "In this study, we examined the putative in vitro and in vivo anti-cancer effects of the specific CXCR4 inhibitor AMD3465. "
11/03/2014 - "Our data demonstrated that N-[(11)C]methyl-AMD3465 is capable of detecting physiologic CXCR4 expression in tumors and other CXCR4 expressing tissues. "
06/01/2011 - "Treatment with AMD3465 inhibited uptake of radioactivity by the tumors in both models. "
11/03/2014 - "Ex vivo biodistribution and PET imaging of N-[(11)C]methyl-AMD3465 were performed in rats with C6 tumor xenografts. "
08/01/2014 - "The biodistribution and PET/CT imaging studies with the radiolabeled bridged cyclams demonstrated longer tumor retention and comparable uptake to [(64)Cu]AMD3465, though [(64)Cu]AMD3465 demonstrated superior overall pharmacokinetics. "
|2.||Neoplasm Metastasis (Metastasis)
01/01/2013 - "The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo."
01/01/2013 - "In conclusion, our studies suggest that AMD3465 inhibits breast cancer growth and metastases by acting on tumor cells as well as immune cells that constitute the tumor microenvironment. "
01/01/2013 - "Using three breast cancer cell lines as murine syngeneic immunocompetent breast cancer models, we found that AMD3465 inhibited breast tumor formation and reduced tumor cell metastases to the lung and liver. "
06/11/2009 - "In vivo studies demonstrated that AMD3465, alone or in combination with granulocyte colony-stimulating factor, induced mobilization of AML cells and progenitor cells into circulation and enhanced antileukemic effects of chemotherapy and sorafenib, resulting in markedly reduced leukemia burden and prolonged survival of the animals. "
08/01/2006 - "The present study tested a second generation CXCR4 antagonist, AMD3465, for effects on highly defined models of Th1- and Th2-cell-mediated hypersensitivity-type pulmonary granuloma formation. "
08/01/2006 - "AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation."
|2.||Granulocyte Colony-Stimulating Factor (G-CSF)
|3.||sorafenib (BAY 43-9006)
|4.||CXCR4 Receptors (CXCR4 Receptor)
|6.||Interleukin-10 (Interleukin 10)
|7.||Proteins (Proteins, Gene)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)